Holdbrook Mark J. has filed 5 insider transactions across 1 company since March 2023.
Most recent transaction: a sale of 188 shares of Tarsus Pharmaceuticals, Inc. ($TARS) on March 17, 2023.
Activity breakdown: 0 open-market purchases and 3 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2023 | Tarsus Pharmaceuticals, Inc. | $TARS | Holdbrook Mark J. | V.P., Clinical Affairs | S | Common Stock | 188 | $13.28 | 3,389.0000 | 24,619,700 | 5.26% | 0.00% |
| March 20, 2023 | Tarsus Pharmaceuticals, Inc. | $TARS | Holdbrook Mark J. | V.P., Clinical Affairs | S | Common Stock | 198 | $12.61 | 3,191.0000 | 24,619,700 | 5.84% | 0.00% |
| March 15, 2023 | Tarsus Pharmaceuticals, Inc. | $TARS | Holdbrook Mark J. | V.P., Clinical Affairs | M | Common Stock | 2653 | $0.00 | 3,764.0000 | 24,619,700 | 238.79% | 0.01% |
| March 16, 2023 | Tarsus Pharmaceuticals, Inc. | $TARS | Holdbrook Mark J. | V.P., Clinical Affairs | S | Common Stock | 187 | $13.43 | 3,577.0000 | 24,619,700 | 4.97% | 0.00% |
| March 15, 2023 | Tarsus Pharmaceuticals, Inc. | $TARS | Holdbrook Mark J. | V.P., Clinical Affairs | M | Restricted Stock Units | 2653 | $0.00 | 7,959.0000 | 24,619,700 | 25.00% | 0.01% |